Lipoma Preferred Partner Antibody

Lipoma preferred partner (LPP) is encoded by the preferred fusion partner gene of the high mobility group protein HMGI-C. LPP is frequently affected by chromosomal translocations in a major group of soft tissue lipomas, as well as in a parosteal lipoma and in pulmonary chondroid hamartomas. The resulting fusion proteins comprise three DNA binding domains of HMGI-C fused to two or three C-terminal LIM domains of LPP and a reciprocal product, respectively. Expression of a HMGI-C/LPP fusion protein causes malignant transformation of fibroblasts. Similar to its relatives zyxin and TRIP (thyroid receptor interacting protein 6) / ZRP-1 (zyxin-related protein 1), LPP consists of a N-terminal proline-rich domain followed by three C-terminal LIM domains (double zinc finger structures that are involved in protein-protein interactions) . Like the cytoskeletal protein zyxin, LPP localizes to focal adhesions and cell-cell adherens junctions. LPP harbors a nuclear export signal and displays transcriptional activation capacity.

Immunocytochemistry: (1:500) . Immunohistochemistry: (1:500) . Western Blot: (1:1,000) . Optimal conditions must be determined individually for each application.